SILO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Silo Pharma Inc (SILO.O) is -0.48, compared to its 5-year average forward P/E of -1.22. For a more detailed relative valuation and DCF analysis to assess Silo Pharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.22

Current PE

-0.48

Overvalued PE

-0.04

Undervalued PE

-2.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

48.03

Current PS

62.08

Overvalued PS

90.10

Undervalued PS

5.95

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SILO News & Events

Events Timeline

No data

News

3.5

2025-12-30Globenewswire

Silo Pharma Partners with Allucent to Advance SPC-15 Clinical Studies

3.5

2025-12-30Newsfilter

Silo Pharma Enters LOI with Allucent for SPC-15 Clinical Studies

9.0

2025-11-17Newsfilter

Silo Pharma Collaborates with Allucent to Assist in Upcoming FDA Investigational New Drug Application for SPC-15 as a PTSD Treatment

People Also Watch

Frequently Asked Questions

What is Silo Pharma Inc (SILO) stock price today?

The current price of SILO is 0.3926 USD — it has increased 1.03 % in the last trading day.

What is Silo Pharma Inc (SILO)'s business?

Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

What is the price predicton of SILO Stock?

Wall Street analysts forecast SILO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SILO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Silo Pharma Inc (SILO)'s revenue for the last quarter?

Silo Pharma Inc revenue for the last quarter amounts to 18.03K USD, decreased 0.00 % YoY.

What is Silo Pharma Inc (SILO)'s earnings per share (EPS) for the last quarter?

Silo Pharma Inc. EPS for the last quarter amounts to -0.12 USD, decreased -45.45 % YoY.

What changes have occurred in the market's expectations for Silo Pharma Inc (SILO)'s fundamentals?

The market is revising No Change the revenue expectations for SILO for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -30.14%.

How many employees does Silo Pharma Inc (SILO). have?

Silo Pharma Inc (SILO) has 3 emplpoyees as of January 10 2026.

What is Silo Pharma Inc (SILO) market cap?

Today SILO has the market capitalization of 5.23M USD.